[Therapy-related acute myeloid leukemia following double autologous peripheral blood stem cell transplantation for non-Hodgkin's lymphoma].

Abstract

A 29-year-old male was diagnosed as having non-Hodgkin's lymphoma (NHL, diffuse, large cell, B-cell, stage IV) in June 1999. He underwent 7 courses of chemotherapy and double autologous peripheral stem cell transplantation (total dose: CPA 13,000 mg, BUS 892 mg, L-PAM 150 mg, MCNU 870 mg, MTX 60 mg, Ara-C 160 mg, DXR 350 mg, VP-16 11,190 mg, VCR 8 mg, CBDCA 700 mg, and MIT 22 mg) for NHL and obtained complete remission in April 2000. In September 2000, he suffered from progressive general malaise. Laboratory findings showed marked leukocytosis with 85% leukemia cells, which were positive for alpha-naphthyl butyrate esterase. Surface-marker analysis of the leukemia cells showed positive results for CD11b, CD11c, CD13, CD15, CD33, CD56, CD64, CD65, CD71 and HLA-DR, and chromosomal analysis revealed add(8) (p11), add(9) (p13). He was diagnosed as having AML (M5a) and was still in complete remission for NHL. He did not respond to chemotherapy and died in December 2000, believed to be from therapy-related leukemia induced by the VP-16 used for treating NHL, judging by the patient's short clinical course and monocytic type of leukemia.

• Authors: Hiroshi Fujii, Toshiki Iwai, Yutaka Ueda, Hitoshi Nakagawa
• Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology (Rinsho Ketsueki) Vol. 43 Issue 6 Pg. 482-7 (Jun 2002) ISSN: 0485-1439 [Print] Japan
• PMID: 12134706 (Publication Type: Case Reports, English Abstract, Journal Article, Review)

Chemical References

• Etoposide

Topics

• Adult
• Antineoplastic Combined Chemotherapy Protocols (adverse effects, therapeutic use)
• Etoposide (administration & dosage, adverse effects)
• Hematopoietic Stem Cell Transplantation
• Humans
• Leukemia, Monocytic, Acute (etiology)
• Lymphoma, B-Cell (drug therapy, therapy)
• Lymphoma, Large B-Cell, Diffuse (drug therapy, therapy)
• Male
• Neoplasms, Second Primary (etiology)